keyword
https://read.qxmd.com/read/38530111/a-low-risk-hpv-associated-well-differentiated-squamous-cell-carcinoma-of-the-cervix-with-low-grade-squamous-intraepithelial-lesion-morphology-clinical-and-pathologic-diagnostic-difficulties-and-review-of-the-literature
#1
JOURNAL ARTICLE
Deniz Ates, Esra Nur Sahin, Kübra Katipoglu, Alp Usubutun
Approximately 95% of cervical squamous cell carcinomas are associated with high-risk HPV, with a small number of HPV-independent tumors. However, low-risk HPV types have also been detected in rare cervical squamous cell carcinomas. Low-grade squamous intraepithelial lesion-related changes are a rare morphologic finding in cervical squamous cell carcinoma. We present the case of a 30-yr-old woman who presented with pelvic pain and foul-smelling vaginal discharge showing an exophytic lesion protruding from the cervix...
March 26, 2024: Türk Patoloji Dergisi
https://read.qxmd.com/read/38524643/multidisciplinary-treatment-for-small-cell-carcinoma-of-the-bladder-a-case-report
#2
JOURNAL ARTICLE
Yoshie Mita, Jun Teishima, Akihisa Yao, Riku Uematsu, Takahiko Yoshii, Takuto Hara, Masato Fujisawa, Ichiro Nakamura
Small cell carcinoma (SCC) of the urinary bladder is a rare and highly aggressive subtype of bladder cancer. Most cases are diagnosed at advanced stages, and its therapeutic strategy remains unestablished. Here, we report a case of bladder SCC in which multidisciplinary treatment has resulted in relatively long-term survival. A 68-year-old man presented with gross hematuria. A cystoscopy revealed an invasive bladder tumor. A transurethral resection of bladder tumor (TURBT) was performed, and the pathological diagnosis was SCC...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38523484/updates-on-urinary-bladder-tumors-with-neuroendocrine-features
#3
JOURNAL ARTICLE
Dilara Akbulut, Hikmat Al-Ahmadie
The most common neuroendocrine tumor in the urinary bladder is small cell carcinoma, which can be pure or mixed with components of urothelial or other histologic subtypes. Large cell neuroendocrine carcinoma of the bladder is rare and remains ill-defined but is increasingly recognized. Well-differentiated neuroendocrine tumor and paraganglioma can arise in the bladder but are very rare in this location. Recent advances in molecular characterization allowed for better classification and may offer improved stratification of these tumors...
March 25, 2024: Advances in Anatomic Pathology
https://read.qxmd.com/read/38473355/cost-effectiveness-of-treatment-optimisation-with-biomarkers-for-immunotherapy-in-solid-tumours-a-systematic-review
#4
REVIEW
Sara Mucherino, Valentina Lorenzoni, Isotta Triulzi, Marzia Del Re, Valentina Orlando, Annalisa Capuano, Romano Danesi, Giuseppe Turchetti, Enrica Menditto
This study investigated the health economic evaluations of predictive biomarker testing in solid tumours treated with immune checkpoint inhibitors (ICIs). Searching PubMed, EMBASE, and Web of Science from June 2010 to February 2022, 58 relevant articles were reviewed out of the 730 screened. The focus was predominantly on non-small cell lung cancer (NSCLC) (65%) and other solid tumours (40%). Among the NSCLC studies, 21 out of 35 demonstrated cost-effectiveness, notably for pembrolizumab as first-line treatment when preceded by PD-L1 assessment, cost-effective at a threshold of $100,000/QALY compared to the standard of care...
February 29, 2024: Cancers
https://read.qxmd.com/read/38461779/reduced-burden-of-arsenic-related-cancers-after-water-mitigation-in-taiwan
#5
JOURNAL ARTICLE
Jing-Rong Jhuang, Chih-Hung Lee, Chun-Ju Chiang, Chien-Jen Chen, Wen-Chung Lee
BACKGROUND: Epidemiological evidence has demonstrated an association between arsenic in drinking water and increased cancer incidence. This population-based study investigates the impact of a tap water supply system installation in Blackfoot disease-endemic regions of Taiwan on cancer incidence. METHODS: By using the Taiwan Cancer Registry dataset, we enrolled patients aged 40-84 diagnosed with arsenic-related cancers, including hepatocellular carcinoma, small and squamous cell lung cancer, Bowen's disease, basal and squamous cell skin cancer, urothelial bladder cancer, and upper tract urothelial carcinoma between 1995 and 2019...
March 5, 2024: Environment International
https://read.qxmd.com/read/38434685/genetic-prediction-of-the-causal-relationship-between-schizophrenia-and-tumors-a-mendelian-randomized-study
#6
JOURNAL ARTICLE
Xintong Zhou, Qi Liu, Shihan Liu, Liquan Wang, Zhongli Sun, Changgang Sun, Xiangning Cui
BACKGROUND: Patients with schizophrenia are at a higher risk of developing cancer. However, the causal relationship between schizophrenia and different tumor types remains unclear. METHODS: Using a two-sample, two-way Mendelian randomization method, we used publicly available genome-wide association analysis (GWAS) aggregate data to study the causal relationship between schizophrenia and different cancer risk factors. These tumors included lung adenocarcinoma, lung squamous cell carcinoma, small-cell lung cancer, gastric cancer, alcohol-related hepatocellular cancer, tumors involving the lungs, breast, thyroid gland, pancreas, prostate, ovaries and cervix, endometrium, colon and colorectum, and bladder...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38420082/small-cell-carcinoma-of-the-gall-bladder-a-rare-tumor-of-the-gall-bladder
#7
Anuradha S Dnyanmote, Kuldip Patil, Vidita Modi, Rushi Kanani
Small-cell carcinoma (SCC) of the gallbladder is a rare and distinctive clinicopathological entity, characterized by its aggressive nature with early metastasis and a poor prognosis. We present a rare case of a 53-year-old female who came with a perforated gall bladder and was later diagnosed with SCC. This report details how the patient was managed preoperatively, intraoperatively, and postoperatively. The patient is under follow-up and has survived so far with subsequent chemotherapy.
January 2024: Curēus
https://read.qxmd.com/read/38396726/differentially-expressed-genes-involved-in-primary-resistance-to-immunotherapy-in-patients-with-advanced-stage-pulmonary-cancer
#8
JOURNAL ARTICLE
Luis Miguel Chinchilla-Tábora, Juan Carlos Montero, Luis Antonio Corchete, Idalia González-Morais, Edel Del Barco Morillo, Alejandro Olivares-Hernández, Marta Rodríguez González, José María Sayagués, María Dolores Ludeña
In the last few years, nivolumab has become the standard of care for advanced-stage lung cancer patients. Unfortunately, up to 60% of patients do not respond to this treatment. In our study, we identified variations in gene expression related to primary resistance to immunotherapy. Bronchoscopy biopsies were obtained from advanced non-small cell lung cancer (NSCLC) patients previously characterized as responders or non-responders after nivolumab treatment. Ten tumor biopsies (from three responders and seven non-responders) were analyzed by the differential expression of 760 genes using the NanoString nCounter platform...
February 8, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38396316/metastatic-upper-tract-urothelial-carcinoma-with-nest-like-features-presenting-as-malignant-pleural-effusion
#9
JOURNAL ARTICLE
Francesca Arienzo, Alessandra Valenti, Paolo Ricci, Valeria Ascoli
Metastatic urothelial carcinoma is a rare cause of pleural effusions. We report a case of urothelial carcinoma of the upper urinary tract in an oldest-old male patient, a smoker, with situs inversus totalis, that presented uniquely with malignant pleural effusion at presentation without evidence of a primary tumor on imaging. Cytological smears of the massive left pleural effusion revealed epithelioid neoplastic cells arranged in short cords, small-to-large clusters, and raspberry-like morules, mimicking mesothelioma; cell block preparations highlighted the presence of tubules and nest-like structures...
February 23, 2024: Diagnostic Cytopathology
https://read.qxmd.com/read/38395384/related-cellular-signaling-and-consequent-pathophysiological-outcomes-of-ubiquitin-specific-protease-24
#10
REVIEW
Xiaoyang Song, Boyu Xia, Xinrong Gao, Xinying Liu, Hongyuan Lv, Shiwei Wang, Qinpei Xiao, Hao Luo
Ubiquitin-specific protease 24 (USP24) is an essential member of the deubiquitinating protease family found in eukaryotes. It engages in interactions with multiple proteins, including p53, MCL-1, E2F4, and FTH1, among others. Through these interactions, USP24 plays a critical role in regulating vital cellular processes such as cell cycle control, DNA damage response, cellular iron autophagy, and apoptosis. Increased levels of USP24 have been observed in various cancer types, including bladder cancer, lung cancer, myeloma, hepatocellular carcinoma, and gastric cancer...
February 21, 2024: Life Sciences
https://read.qxmd.com/read/38386805/sacituzumab-govitecan-plus-platinum-based-chemotherapy-mediates-significant-antitumor-effects-in-triple-negative-breast-urinary-bladder-and-small-cell-lung-carcinomas
#11
JOURNAL ARTICLE
Thomas M Cardillo, Maria B Zalath, Roberto Arrojo, Robert M Sharkey, Serengulam V Govindan, Chien-Hsing Chang, David M Goldenberg
Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer...
February 22, 2024: Oncotarget
https://read.qxmd.com/read/38380948/cytomorphology-of-metastatic-dedifferentiated-undifferentiated-melanoma-to-the-gallbladder-a-case-report-and-review-of-literature
#12
JOURNAL ARTICLE
Shaymaa Hegazy, Zarine Kamaluddin, Rana Naous
Dedifferentiated/undifferentiated melanoma (DM/UM) is a distinct subtype of malignant melanoma that tends to lose all melanocytic markers of differentiation. DM/UM pose major diagnostic challenges as they could be easily confused with UM sarcoma or carcinoma, thus necessitating the use of molecular studies such as Next Generation Sequencing (NGS) for detecting melanoma-compatible mutations to confirm such diagnosis. The capability of performing NGS molecular studies on small biopsy material with confirmation of adequacy via rapid on-site evaluation (ROSE) has tremendous value in diagnosing DM/UM...
February 21, 2024: Diagnostic Cytopathology
https://read.qxmd.com/read/38369265/pan-cancer-analysis-predicts-cant1-as-a-potential-prognostic-immunologic-biomarker
#13
JOURNAL ARTICLE
Wei Yang, Zhidong Liu, Ting Liu
BACKGROUND: CANT1, calcium-activated nucleotidase 1, was reported to be upregulated in certain tumors. However, the function mechanism of CANT1 in pan-cancer is still unclear. METHODS: We utilized the Cancer Genome Atlas Program (TCGA) and UALCAN databases to analyze CANT1 expression at the level of mRNA, protein, and promoter methylation in pan-cancer, and the cBioportal database to study the frequency of gene changes for CANT1. Wilcoxon rank-sum test was applied to discuss the correlation between CANT1 and clinicopathological features in different types of tumor...
February 16, 2024: Cellular Signalling
https://read.qxmd.com/read/38321289/molecular-profile-of-bladder-cancer-progression-to-clinically-aggressive-subtypes
#14
REVIEW
Charles C Guo, Sangkyou Lee, June G Lee, Huiqin Chen, Michael Zaleski, Woonyoung Choi, David J McConkey, Peng Wei, Bogdan Czerniak
Bladder cancer is a histologically and clinically heterogenous disease. Most bladder cancers are urothelial carcinomas, which frequently develop distinct histological subtypes. Several urothelial carcinoma histological subtypes, such as micropapillary, plasmacytoid, small-cell carcinoma and sarcomatoid, show highly aggressive behaviour and pose unique challenges in diagnosis and treatment. Comprehensive genomic characterizations of the urothelial carcinoma subtypes have revealed that they probably arise from a precursor subset of conventional urothelial carcinomas that belong to different molecular subtypes - micropapillary and plasmacytoid subtypes develop along the luminal pathway, whereas small-cell and sarcomatoid subtypes evolve along the basal pathway...
February 6, 2024: Nature Reviews. Urology
https://read.qxmd.com/read/38298282/long-term-survival-after-definitive-concurrent-chemoradiation-therapy-for-synchronous-small-cell-neuroendocrine-carcinoma-of-the-urinary-bladder-and-adenocarcinoma-of-the-prostate-a-case-report
#15
Michael T Hsieh, Richard Tustin, Tue Le, Abdul Rahim Mohd Tahir, Thomas P Shakespeare
Available reports of synchronous prostate and bladder cancer have exclusively described radical cystoprostatectomy with or without perioperative chemotherapy as the treatment of choice. There are no reports of curative intent or definitive chemoradiation therapy for synchronous primary bladder and primary prostate cancers. Small cell carcinoma of the bladder is a rare and aggressive tumor. We present the first case of synchronous mixed small cell carcinoma and urothelial carcinoma of the urinary bladder and adenocarcinoma of the prostate in a 70-year-old male who attained long-term survival after curative intent and definitive concurrent chemoradiotherapy with minimal acute and late toxicities...
January 2024: Curēus
https://read.qxmd.com/read/38288815/an-expedition-on-synthetic-methodology-of-fda-approved-anticancer-drugs-2018-2021
#16
JOURNAL ARTICLE
Vishakha S, Navneesh N, Balak Das Kurmi, Ghanshyam Das Gupta, Sant Kumar Verma, Ankit Jain, Preeti Patel
New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (Erwiniachrysanthemi-derived asparaginase) approved by the U...
January 29, 2024: Anti-cancer Agents in Medicinal Chemistry
https://read.qxmd.com/read/38271200/gad2-is-a-highly-specific-marker-for-neuroendocrine-neoplasms-of-the-pancreas
#17
JOURNAL ARTICLE
Maximilian Lennartz, Nick Benjamin Dünnebier, Doris Höflmayer, Sebastian Dwertmann Rico, Simon Kind, Viktor Reiswich, Florian Viehweger, Florian Lutz, Christoph Fraune, Natalia Gorbokon, Andreas M Luebke, Claudia Hube-Magg, Franziska Büscheck, Anne Menz, Ria Uhlig, Till Krech, Andrea Hinsch, Eike Burandt, Guido Sauter, Ronald Simon, Martina Kluth, Stefan Steurer, Andreas H Marx, Patrick Lebok, David Dum, Sarah Minner, Frank Jacobsen, Till S Clauditz, Christian Bernreuther
Glutamate decarboxylase 2 (GAD2) is the most important inhibitory neurotransmitter and plays a role in insulin-producing β cells of pancreatic islets. The limitation of GAD2 expression to a few normal cell types makes GAD2 a potential immunohistochemical diagnostic marker. To evaluate the diagnostic utility of GAD2 immunohistochemistry, a tissue microarray containing 19,202 samples from 152 different tumor entities and 608 samples of 76 different normal tissue types was analyzed. In normal tissues, GAD2 staining was restricted to brain and pancreatic islet cells...
April 1, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38250697/successful-bladder-sparing-partial-cystectomy-for-muscle-invasive-domal-urothelial-carcinoma-with-sarcomatoid-differentiation-a-case-report
#18
Mark Sultan, Ahmad Abdelaziz, Muhammed A Hammad, Juan R Martinez, Shady A Ibrahim, Mahra Nourbakhsh, Ramy F Youssef
High-grade (HG) urothelial carcinoma (UC) with variant histology has historically been managed conservatively. The presented case details a solitary lesion of muscle-invasive bladder cancer (MIBC) with sarcomatoid variant (SV) histology treated by partial cystectomy (PC) and adjuvant chemotherapy. A 71-year-old male with a 15-pack year smoking history presented after outside transurethral resection of bladder tumor (TURBT). Computerized tomography imaging was negative for pelvic lymphadenopathy, a 2 cm broad-based papillary tumor at the bladder dome was identified on office cystoscopy...
2024: Therapeutic Advances in Urology
https://read.qxmd.com/read/38229092/usp5-facilitates-bladder-cancer-progression-by-stabilizing-the-c-jun-protein
#19
JOURNAL ARTICLE
Hui-Hui Zhang, An-Qi Zhang, Peng Peng, Liang Huang, Cai-Ying Liu, Xin-Rui Nie, De-Fu Hou, Xia Zhang, Shang-Ze Li
BACKGROUND: Bladder cancer is the second most common genitourinary malignancy worldwide. The death rate of bladder cancer has increased every year. However, the molecular mechanism of bladder cancer is not sufficiently studied. Deubiquitinating enzymes (DUBs) play an important role in carcinogenesis. Several studies have demonstrated that USP5 associated with malignancy and pathological progression in hepatocellular carcinoma, colorectal and non-small cell lung cancer. However, the role of USP5 in bladder cancer need to be explored...
January 16, 2024: Cancer Cell International
https://read.qxmd.com/read/38226313/inflammatory-response-signature-score-model-for-predicting-immunotherapy-response-and-pan-cancer-prognosis
#20
JOURNAL ARTICLE
Shuzhao Chen, Mayan Huang, Limei Zhang, Qianqian Huang, Yun Wang, Yang Liang
BACKGROUND: Inflammatory responses influence the outcome of immunotherapy and tumorigenesis by modulating host immunity. However, systematic inflammatory response assessment models for predicting cancer immunotherapy (CIT) responses and survival across human cancers remain unexplored. Here, we investigated an inflammatory response score model to predict CIT responses and patient survival in a pan-cancer analysis. METHODS: We retrieved 12 CIT response gene expression datasets from the Gene Expression Omnibus database (GSE78220, GSE19423, GSE100797, GSE126044, GSE35640, GSE67501, GSE115821 and GSE168204), Tumor Immune Dysfunction and Exclusion database (PRJEB23709, PRJEB25780 and phs000452...
December 2024: Computational and Structural Biotechnology Journal
keyword
keyword
68849
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.